Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

IBC 2023

Intercepting Blood Cancers
03–05 March 2023 | Madrid, Spain

IBC 2023

Intercepting Blood Cancers
03–05 March 2023 | Madrid, Spain

The inaugural Intercepting Blood Cancers (IBC) 2023 Meeting brought together leading experts to discuss precursor conditions in blood cancers including monoclonal B lymphocytosis (MBL), chronic lymphocytic leukemia (CLL) and low-grade lymphoma, myelodysplastic syndromes (MDS) and clonal hematopoiesis of indeterminate potential (CHIP), multiple myeloma (MM), smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS).

IBC 2025 was supported by Johnson & Johnson, Regeneron, AbbVie, Lilly, Sanofi, AstraZenca, TenSixteenBio and the Leukemia & Lymphoma Society. Supporters have no influence over the production of the content.

MBL-CLL/Low-grade Lymphoma CHIP/MDS MM/SMM/MGUS Keynote lecture: regulatory considerations for heme diseases

MBL-CLL/Low-grade Lymphoma
Topic 1.2: The role of MBL in the etiology of CLL

Andrew Rawstron
Low- and high-count MBL: Prevalence and consequences
Andrew Rawstron Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Francesco Forconi
CLL cell surface IgM levels, escape of BTK inhibition
Francesco Forconi University of Southampton, Southampton, United Kingdom

MBL-CLL/Low-grade Lymphoma
Topic 1.3: Precursor conditions in Waldenström Macroglobulinemia

Bruno Paiva
Pre-neoplastic somatic mutations and malignant transformation
Bruno Paiva University of Navarra, Pamplona, Spain
Kostas Stamatopoulos
CBL-MZ; precursor of SMZL
Kostas Stamatopoulos Center for Research and Technology Hellas, Thessaloniki, Greece

MBL-CLL/Low-grade Lymphoma
Topic 2.1: Overview of progression in MBL

Julia Almeida
Early/highly sensitive detection of MBL
Julia Almeida University of Salamanca, Salamanca, Spain
Kostas Stamatopoulos
The BCR repertoire in MBL vs CLL: role in disease progression
Kostas Stamatopoulos Center for Research and Technology Hellas, Thessaloniki, Greece
Alberto Orfao
Immune dysregulation in MBL
Alberto Orfao University of Salamanca, Salamanca, Spain

MBL-CLL/Low-grade Lymphoma
Topic 2.2: Indolent to aggressive: Progression of CLL and FL

Giovanni Tonon
Technologies for detecting progression: Single-cell analysis technologies
Giovanni Tonon San Raffaele Scientific Institute, Milan, Italy
Iñaki Martín-Subero
Early detection of risk-of-progression of CLL to Richter syndrome
Iñaki Martín-Subero Clinic Barcelona, Barcelona, Spain

MBL-CLL/Low-grade Lymphoma
Topic 3.1: Overview of ongoing clinical studies and preliminary data

Inhye Ahn
NeoVax CLL study - development of a personalized vaccine
Inhye Ahn Dana-Farber Cancer Institute, Boston, MA, United States

MBL-CLL/Low-grade Lymphoma
Topic 4.1: TCUS and T-cell LGL leukemia – laboratory diagnostics

Julia Almeida
TCUS and T-cell LGL leukemia
Julia Almeida University of Salamanca, Salamanca, Spain
Gianpietro Semenzato
Morphologic, immunophenotypic and molecular features of T-LGL leukemia
Gianpietro Semenzato Veneto Institute of Molecular Medicine, Padova , Italy

CHIP/MDS
Topic 1.1 Genomics/observational

George Vassiliou
Natural History/dynamics
George Vassiliou University of Cambridge, Cambridge, United Kingdom
Siddhartha Kar
Genetic predisposition
Siddhartha Kar University of Cambridge, Cambridge, United Kingdom
Alexander Bick
Ageing and clonal expansion rate
Alexander Bick Vanderbilt University Medical Center, Nashville, TN, United States
Jamie Blundell
Copy number
Jamie Blundell University of Cambridge, Cambridge, United Kingdom

CHIP/MDS
Topic 1.2: Molecular mechanisms

Lachelle Weeks
Myeloid/lymphoid somatic gene mutations
Lachelle Weeks Dana-Farber Cancer Institute, Boston, MA, United States

CHIP/MDS
Topic 2.1: Prediction of adverse outcomes

Lachelle Weeks
Predictive models – Lesson from population-based studies
Lachelle Weeks Dana-Farber Cancer Institute, Boston, MA, United States
Kelly Bolton
Context-dependent risk factors
Kelly Bolton Washington University in St. Louis, St. Louis, MO, United States

CHIP/MDS
Topic 2.2: Clonal hematopoiesis in the clinics

Luca Malcovati
CHIP, CCUS and early MDS - classification & predictive models
Luca Malcovati University of Pavia, Pavia, Italy
Lucy Godley
CHIP and genetic predisposition
Lucy Godley University of Chicago, Chicago, IL, United States

CHIP/MDS
Topic 3.1: Pre-clinical

John Pimanda
Epigenetic studies
John Pimanda University of New South Wales, Sydney, Australia
Iannis Aifantis
Mechanisms of immune evasion in myeloid malignancies
Iannis Aifantis University of New York, New York City, NY, United States
Ravi Majeti
Pre-clinical studies targeting clonal hematopoiesis HSPCs
Ravi Majeti Stanford University School of Medicine, Stanford, CA, United States

CHIP/MDS
Topic 3.2: Clinical

Mrinal Patnaik
Vitamin C
Mrinal Patnaik Mayo Clinic, Rochester, MN, United States
Kirsten Grønbaek
Oral vitamin C and Metformin in CCUS
Kirsten Grønbaek University of Copenhagen, Copenhagen, Denmark
Uma Borate
Anti-IL1
Uma Borate Ohio State University, Columbus, OH, United States

MM/SMM/MGUS
Topic 1.1: Genomics of MGUS and SMM

Felipe Prósper
Epigenetics of transformation
Felipe Prósper University of Navarra, Navarra, Spain
Irene Ghobrial
Molecular classification of SMM
Irene Ghobrial Dana-Farber Cancer Institute, Boston, MA, United States

MM/SMM/MGUS
Topic 1.2: Animal models to study disease progression

José Ángel Martínez-Climent
Genetic transition under immunocompetence
José Ángel Martínez-Climent University of Navarra, Pamplona, Spain
Adam Sperling
In vivo model systems
Adam Sperling Dana-Farber Cancer Institute, Boston, MA, United States

MM/SMM/MGUS
Topic 1.3: Immune microenvironment of MGUS and smoldering myeloma

Gad Getz
Early immune derailment
Gad Getz Broad Institute, Boston, MA, United States
Romanos Sklavenitis-Pistofidis
Immune biomarkers of response to therapy, immune MRD
Romanos Sklavenitis-Pistofidis Dana-Farber Cancer Institute, Boston, MA, United States
Urvi Shah
Metabolomics and the immune system
Urvi Shah Memorial Sloan Kettering Cancer Center, New York City, NY, United States

MM/SMM/MGUS
Topic 2.1: MGUS/SMM screening and risk

Rafael Fonseca
Natural history of MGUS
Rafael Fonseca Mayo Clinic, Phoenix, AZ, United States
Sigurdur Kristinsson
iStopMM
Sigurdur Kristinsson University of Iceland, Rekjavik, Iceland
Angela Dispenzieri
Is MGUS a benign disease?
Angela Dispenzieri Mayo Clinic, Rochester, MN, United States

MM/SMM/MGUS
Topic 2.2: Risk factors and classification in SMM

Elizabeth O'Donnell
Progress from the 20/20/20 classification
Elizabeth O'Donnell Massachusetts General Hospital, Boston, MA, United States
Bruno Paiva
Immune biomarkers and circulating tumor cells
Bruno Paiva University of Navarra, Pamplona, Spain
Efstathios Kastritis
Clinical and bone biomarkers including the PANGEA model
Efstathios Kastritis National and Kapodistrian University of Athens, Athens, Greece

MM/SMM/MGUS
Topic 3.1: Clinical trials

Shaji Kumar
Phase 2 trials
Shaji Kumar Mayo Clinic, Rochester, MN, United States
Maria Victoria Mateos
Phase 3 trials
Maria Victoria Mateos University Hospital of Salamanca, Salamanca, Spain
Omar Nadeem
Trials in immunotherapy
Omar Nadeem Dana-Farber Cancer Institute, Boston, MA, United States

Keynote: FDA presentation (plenary session)

Nicole Gormley
Regulatory concerns for heme precursor diseases
Nicole Gormley Food and Drug Administration (FDA), Bethesda, MD, United States

The content of VJHemOnc is intended for healthcare professionals